Our Solutions
Genome Editing: CRISPR Services
Custom CRISPR Knock-Out & Knock-In Cell Line Engineering
Rhine Biosciences delivers custom CRISPR/Cas9 cell line engineering for biotech and pharma teams that need precise, fully validated edits in mammalian cell systems. We design, build, and characterize knockout (KO) and knock-in (KI) cell lines across a broad panel of immortalized and disease-relevant backgrounds, giving discovery teams the confidence to interpret pharmacology and translate findings forward.
Every CRISPR cell line we deliver is sequence-verified, clonally derived, and quality-controlled — so your team can focus on biology, not on troubleshooting reagents.
Capabilities
- Gene knockouts — single, double, and triple KO clones in cell lines of your choice.
- Knock-in edits — point mutations, fluorescent tags (GFP, mCherry), epitope tags (FLAG, HA, V5), and inducible systems.
- Endogenous reporter cell line generation for pathway, transcription-factor, and biomarker readouts.
- Clonal isolation, single-cell expansion, and full sequence verification (Sanger and NGS).
- Off-target analysis and karyotype-stability assessment for clinically-translatable lines.
Applications
CRISPR-engineered cell lines from Rhine Biosciences support target validation, mechanism-of-action studies, synthetic-lethality screens, functional genomics, biomarker assay development, and cell-based assays for high-throughput screening. Custom edits can be delivered in your preferred parental line or selected from our recommended panels for oncology, immunology, and metabolic-disease research.
Cell & iPSC Banking
Primary Cells & iPSC Screening Banks: Human, Mouse, Rat & Cynomolgus
Rhine Biosciences supplies disease-relevant primary cells and induced pluripotent stem cells (iPSCs) for translational discovery programs. Our screening banks span human, mouse, and rat primary cell donors, complemented by human iPSCs and cynomolgus (Cyno) iPSCs — a rare offering that enables cross-species pharmacology and safety bridging from preclinical models to first-in-human studies.
Whether you are building a screening campaign, validating a target across species, or modeling a specific patient phenotype, our scientific team will work with you to scope the right donor profile, tissue source, and assay-ready format for your project.
What We Offer
- Human, mouse, and rat primary cells across multiple tissue and cell types.
- Donor-matched and disease-state cell collections for stratified screening.
- Human iPSCs suitable for differentiation into disease-relevant lineages (neurons, hepatocytes, cardiomyocytes, immune cells).
- Cynomolgus (Cyno) iPSCs for cross-species translational research and primate safety bridging.
- Custom screening banks built around your target, indication, or donor inclusion criteria.
Applications
Rhine's primary cells and iPSC lines power phenotypic screening, disease modeling, target pharmacology validation, biomarker discovery, immuno-oncology assays, and cross-species safety profiling. Cyno iPSCs are especially valuable when translating efficacy and toxicity findings from rodent models into non-human primate and clinical programs.
Toxicity Testing
High-Throughput 2D & 3D Spheroid Toxicity Assessment in Cancer Cell Lines
Rhine Biosciences runs validated in vitro toxicity programs in cancer cell lines, generating decision-grade cytotoxicity data in both 2D monolayer and 3D spheroid formats. Our high-throughput (HT) platform delivers consistent, scalable readouts for lead prioritization, on-target and off-target profiling, and therapeutic-index estimation across oncology pipelines.
3D tumor spheroids better recapitulate the architecture, gradients, and drug-penetration challenges of solid tumors — making them a more translational complement to traditional 2D cytotoxicity screens. Our integrated 2D/3D workflow gives discovery teams a single dataset they can act on.
Capabilities
- 2D cancer cell line cytotoxicity in 96- and 384-well high-throughput format.
- 3D tumor spheroid toxicity assays with multi-parametric viability and growth readouts.
- IC50, EC50, and full dose–response characterization with curve fitting and QC.
- Multi-cell-line panels for selectivity and indication-mapping profiling.
- Custom assay design for emerging modalities — small molecules, biologics, ADCs, and bispecifics.
Applications
Apply Rhine's toxicity assays to lead optimization, on-target safety profiling, combination screening, biomarker-guided patient stratification, and translational risk assessment. HT throughput means you can profile libraries, not just hits — accelerating triage and reducing late-stage attrition.
Target Validation
Preclinical Target Validation: Depth of Biology for Confident Decisions
Rhine Biosciences delivers preclinical target validation programs that build conviction in the biology behind every candidate. We design integrated validation strategies — combining genetic perturbation, pharmacological tools, and disease-relevant cellular models — to characterize a target's role, tractability, and translational relevance before significant capital is committed to lead optimization.
Our validation packages are tailored to where your target sits on the maturity curve: from de novo characterization of a novel target nominated from human data, to deep mechanistic and translational profiling of an established target in a crowded class.
How We Validate
- Loss-of-function and gain-of-function studies using CRISPR knockouts, knock-ins, and orthogonal tool compounds.
- Pathway, network, and mechanism-of-action characterization with transcriptomic and proteomic readouts.
- Disease-relevant primary, iPSC-derived, and co-culture model deployment for translationally meaningful phenotypes.
- Phenotypic readouts aligned to clinically-tracked endpoints and biomarkers.
- Biomarker hypothesis generation and translational planning to support clinical-development decisions.
Applications
Use Rhine's target validation services to support target nomination decisions, IND-enabling biology, indication selection, patient-stratification strategy, and competitive differentiation in crowded target classes. Validation outputs are delivered as structured data packages that can plug directly into your scientific review and investment committees.
AI Target Nominations
AI Target Nomination: Human Biobank Data, AI-Enabled Discovery
Rhine Biosciences turns large-scale human biobank data into actionable target hypotheses. Our AI target nomination packages integrate multi-omics, genetic, and clinical evidence from human cohorts to identify, prioritize, and de-risk novel drug targets — anchoring early discovery in human biology rather than model-organism inference.
Programs supported by direct human genetic and multi-omics evidence are substantially more likely to succeed in the clinic. Our AI platform compresses what would otherwise be months of manual curation into structured, defensible nomination packages your team can act on immediately.
What's Inside a Target Nomination Data Package
- AI-driven target identification and ranking across therapeutic areas and indications.
- Multi-omics evidence — genetics, transcriptomics, proteomics, and clinical phenotypes from human biobanks.
- Target tractability, novelty, and competitive-landscape analysis.
- Indication mapping and patient-stratification hypotheses tied to biomarker readouts.
- Translational biomarkers and a clinical-readiness assessment to inform downstream investment.
Why Human-Evidence-First Matters
Targets backed by direct human evidence have higher clinical success rates than those nominated solely from model-organism biology. Rhine's AI target nomination service combines machine-learning models, curated biobank datasets, and expert scientific review — so every nomination is both data-rich and biologically defensible.
Applications
Use AI-nominated target packages to seed new pipelines, expand indications for existing assets, prioritize between competing targets, and brief investment committees with rigorous, human-evidence-anchored science. Nominations can be handed directly into our target validation and CRISPR engineering services for a fully integrated discovery program.
FAQs
Customers have questions, you have answers. Display the most frequently asked questions, so everybody benefits.
Our Services
If customers can’t find it, it doesn’t exist. Clearly list and describe the services you offer. Also, be sure to showcase a premium service.